chronic kidney disease

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

By MedXY 11/11/2025

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention, and treatment is needed.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

By MedXY 11/08/2025

A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

By MedXY 11/08/2025

A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.

Cardiology Nephrology news

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Cardiology Pediatrics Specialties Transplantation

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

By MedXY 10/21/2025

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.

Cardiology Nephrology Specialties

Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients

By MedXY 10/20/2025

This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly patients.

Diabetes & Endocrinology Nephrology Specialties

Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort

By MedXY 10/19/2025

This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.

Cardiology Nephrology news

Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis

By MedXY 10/11/2025

Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.

Cardiology Clinical Updates Nephrology

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY 09/27/2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall major cardiovascular events.

Cardiology Nephrology

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY 09/27/2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise for those with chronic kidney disease.

Clinical Updates Nephrology news

Lubiprostone Therapy in Chronic Kidney Disease: A Phase 2 Trial Reveals Mitochondrial Enhancement via Polyamine Modulation

By MedXY 09/19/2025

A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic avenue.

Nephrology news Specialties

Silent Threats: Why Uremia is Affecting Younger Adults and How to Protect Your Kidneys

By MedXY 08/27/2025

Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prevention strategies.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study

By MedXY 08/23/2025

A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.

Nephrology Oncology Specialties

Predicting Chronic Kidney Disease After Cisplatin Treatment: Insights from Population-Level Data

By MedXY 08/22/2025

Cisplatin chemotherapy is associated with predictable kidney function decline, with pre-treatment eGFR effectively forecasting chronic kidney disease risk post-treatment. Simple models outperform complex approaches, offering practical clinical decision tools.

Nephrology Specialties

Complementary and Alternative Medicine Usage in Chronic Kidney Disease: Prevalence, Patterns, and Clinical Implications

By MedXY 08/21/2025

Complementary and alternative medicine (CAM) use is prevalent in chronic kidney disease (CKD), with 43% of patients globally employing CAM modalities. Nutritional supplements, mind-body practices, and traditional medicines are widely used, yet non-disclosure to healthcare providers is common, underscoring the need for open clinical communication.

Cardiology General Surgery Nephrology Specialties

Perioperative Nitric Oxide Conditioning in Cardiac Surgery: A Paradigm Shift for Protecting Renal Function in CKD Patients (DEFENDER Trial Review)

By MedXY 08/21/2025

Perioperative nitric oxide administration in CKD patients undergoing cardiac surgery significantly reduces acute kidney injury incidence and preserves renal function, while demonstrating safety and additional benefits against postoperative pneumonia.

Cardiology Clinical Updates Nephrology news Specialties

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

By MedXY 08/17/2025

A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.

AI Clinical Updates Nephrology news Specialties

Evaluating Electronic Nudges to Enhance Guideline-Directed Therapy in Chronic Kidney Disease: Insights from the NUDGE-CKD Trial

By MedXY 08/16/2025

The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.